Top

Published in:

01-02-2018

Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy

Authors: Enea Spada, Giovanni Rezza, Anna Rosa Garbuglia, Flavia Lucia Lombardo, Ornella Zuccaro, Francesca Menniti Ippolito, Elisabetta Cupellaro, Stefania Capone, Maria Rosaria Capobianchi, Alfredo Nicosia, Riccardo Cortese, Antonella Folgori, Alfonso Mele, The Collaborative Study Group

Published in: Journal of Urban Health | Issue 1/2018

Abstract

So far, only three small outdated studies have investigated hepatitis C virus (HCV) incidence and risk factors among illicit drug users (DUs) in Italy. Thus, during 2007–2010, we conducted a prospective cohort study among DUs attending 17 Italian rehabilitation centers serving urban areas. Two hundred eighty-four HCV-uninfected DUs were prospectively followed by interview and anti-HCV antibody and RNA testing every 6 months. Incidence was calculated using the person-years method. Infection predictors were assessed by time-dependent Cox analysis. Participants were mostly male (83.4%), under opioid substitution therapy (OST) (78.9%), non-injecting DUs (67.9%), and with a mean age of 30.8. Ninety-one of 224 DUs initially under OST interrupted treatment during the follow-up. Overall HCV incidence was 5.83/100 person-years at risk (PYAR) [95% confidence intervals (CI), 3.63–9.38]. The incidence did not significantly differ according the participants’ sociodemographic characteristics or the degree of urbanization of the towns involved in the study. The incidence was higher for DUs under than for those not under OST (6.23 vs 4.50/100 PYAR; p = 0.681). Incidence was also higher for those with than for those without OST interruption (7.17 vs 5.04/100 PYAR; p = 0.55). However, all these differences were non-significant. At last follow-up visit, a significant decrease in frequency of sharing equipment for preparation/using drugs (by injection or not) was observed by analyzing either the whole cohort or DUs under OST only. Anti-HCV seroconversion resulted independently associated with sharing drug preparation/use equipment, backloading, having a HCV-positive sexual partner, or household and (marginally) intravenous injection. In this study, HCV incidence was non-negligible and OST seemed to lack effectiveness in reducing it. In Italy, implementation of combined harm reduction interventions and antiviral treatment of chronically infected DUs would be needed.

Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.CrossRefPubMedPubMedCentral

Scheinmann R, Hagan H, Lelutiu–Weinberger C, Stern R, et al. Non–injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 2007;89:1–12.CrossRefPubMed

Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta–analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204:74–83.CrossRefPubMedPubMedCentral

Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345.CrossRefPubMedPubMedCentral

Spada E, Mele A, Mariano A, et al. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system. J Med Virol. 2013;85:433–40.CrossRefPubMed

Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104:2740–6.CrossRefPubMed

Fabris P, Baldo V, Baldovin T, et al. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008;42:527–32.CrossRefPubMed

Camoni L, Regine V, Salfa MC, et al. Prevalence and correlates of infection with human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among DUs in Italy: a cross–sectional study. Scand J Infect Dis. 2009;41:520–3.CrossRefPubMed

Stroffolini T, D'Egidio PF, Aceti A, et al. Hepatitis C virus infection among drug addicts in Italy. J Med Virol. 2012;84:1608–12.CrossRefPubMed

10.

Rondy M, Wiessing L, Hutchinson SJ, et al. Hepatitis C prevalence in injecting DUs in Europe, 1990–2007: impact of study recruitment setting. Epidemiol Infect. 2013;141:563–72.CrossRefPubMed

11.

Galeazzi B, Tufano A, Barbierato E, et al. Hepatitis C virus infection in Italian intravenous DUs: epidemiological and clinical aspects. Liver. 1995;15:209–12.CrossRefPubMed

12.

Giuliani M, Caprilli F, Gentili G, et al. Incidence and determinants of hepatitis C virus infection among individuals at risk of sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program. Sex Transm Dis. 1997;24:533–7.CrossRefPubMed

13.

Rezza G, Sagliocca L, Zaccarelli M, et al. Incidence rate and risk factors for HCV seroconversion among injecting DUs in an area with low HIV seroprevalence. Scand J Infect Dis. 1996;28:27–9.CrossRefPubMed

14.

Pouget ER, Hagan H, Des Jarlais DC. Meta–analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction. 2012;107:1057–65.CrossRefPubMedPubMedCentral

15.

Wand H, Spiegelman D, Law M, et al. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Addiction. 2009;104:2049–56.CrossRefPubMed

16.

Craine N, Hickman M, Parry JV, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137:1255–65.CrossRefPubMed

17.

Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558–64.CrossRefPubMed

18.

Hagan H, Pouget ER, Williams IT, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis. 2010;201:378–85.CrossRefPubMed

19.

The Global State of Harm Reduction 2014: available at: https://www.hri.global/files/2015/02/16/GSHR2014.pdf; updated 01/07/2017.

20.

Mazzeo C, Azzaroli F, Giovanelli S, et al. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut. 2003;52:1030–4.CrossRefPubMedPubMedCentral

21.

Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut. 2002;50:693–6.CrossRefPubMedPubMedCentral

22.

Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109:2053–9.

23.

Palmateer NE, Taylor A, Goldberg DJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One. 2014;9:e104515.CrossRefPubMedPubMedCentral

24.

van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22:183–93.CrossRefPubMedPubMedCentral

25.

Lucidarme D, Bruandet A, Ilef D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect. 2004;132:699–708.CrossRefPubMedPubMedCentral

26.

Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106:1978–88.CrossRefPubMed

27.

Palmateer N, Kimber J, Hickman M, et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105:844–59.CrossRefPubMed

28.

Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ. 2005;330:24–5.CrossRefPubMedPubMedCentral

29.

Vallejo F, Barrio G, Brugal MT, et al. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. J Epidemiol Community Health. 2015;69:599–603.CrossRefPubMed

30.

Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction. 2007;102:1454–62.CrossRef

31.

MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25:34–52.CrossRefPubMed

32.

Crofts N, Nigro L, Oman K, et al. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92:999–1005.CrossRefPubMed

33.

Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52:1497–505.CrossRefPubMed

34.

de Waure C, Cefalo C, Chiaradia G, et al. Intrafamilial transmission of hepatitis C virus in Italy: a systematic review. J Epidemiol Community Health. 2010;64:843–8.CrossRefPubMed

35.

Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004;99:855–9.CrossRefPubMed

36.

Kao JH, Liu CJ, Chen PJ, et al. Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol. 2000;15:391–5.CrossRefPubMed

37.

McMahon JM, Pouget ER, Tortu S. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis. 2007;195:1572–81.CrossRefPubMed

38.

Hahn JA, Evans JL, Davidson PJ, et al. Hepatitis C virus risk behaviors within the partnerships of young injecting users. Addiction. 2010;105:1254–64.CrossRefPubMedPubMedCentral

39.

Martino SC, Ellickson PL, McCaffrey DF. Developmental trajectories of substance use from early to late adolescence: a comparison of rural and urban youth. J Stud Alcohol Drugs. 2008;69:430–40.CrossRefPubMedPubMedCentral

40.

Sagliocca L, Rezza G, Vlahov D, et al. A morphine prescription program in Italy (1980–1985): retrospective evidence of protection against HIV/AIDS. Addict Res Theory. 1997;5:137–44.CrossRef

41.

Martin NK, Vickerman P, Grebely J, et al. Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598–609.CrossRefPubMedPubMedCentral

Title: Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy
Authors: Enea Spada
Giovanni Rezza
Anna Rosa Garbuglia
Flavia Lucia Lombardo
Ornella Zuccaro
Francesca Menniti Ippolito
Elisabetta Cupellaro
Stefania Capone
Maria Rosaria Capobianchi
Alfredo Nicosia
Riccardo Cortese
Antonella Folgori
Alfonso Mele
The Collaborative Study Group
Publication date: 01-02-2018
Publisher: Springer US
Published in: Journal of Urban Health / Issue 1/2018
Print ISSN: 1099-3460
Electronic ISSN: 1468-2869
DOI: https://doi.org/10.1007/s11524-017-0207-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

The Costly Consequences of not Being Socially and Behaviorally Ready to Learn by Kindergarten in Baltimore City

Preventing Injection Drug use Initiation: State of the Evidence and Opportunities for the Future

Non-injection Drug Use and Injection Initiation Assistance among People Who Inject Drugs in Tijuana, Mexico

How Many Transgender Men Are There in San Francisco?

The Association Between Apartment Layout and Depressive Symptomology among Hispanic/Latino Residents in Low-Income Housing: the AHOME Study

High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members